Publicaciones (46) Publicaciones de Julian Sanz Ortega

2023

  1. A slightly different polyp: melanoma metastasis diagnosed by colonoscopy

    Revista espanola de enfermedades digestivas, Vol. 115, Núm. 6, pp. 343-344

  2. Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years

    The Journal of urology, Vol. 209, Núm. 1, pp. 261-270

  3. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

  4. Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP

    Revista Espanola de Patologia, Vol. 56, Núm. 4, pp. 261-270

  5. Reply by Authors

    The Journal of urology, Vol. 209, Núm. 1, pp. 270

2022

  1. miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response

    Journal of Hematology and Oncology, Vol. 15, Núm. 1

2019

  1. Prostate pathology recommendations from the Uropathology working group of the Spanish Society of Pathology

    Revista Espanola de Patologia, Vol. 52, Núm. 3, pp. 167-177

2018

  1. Aligning digital CD8 + scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma

    Histopathology, Vol. 72, Núm. 2, pp. 270-284

  2. Durable response to first-line nivolumab in a patient with oligometastatic PD-L1 positive nasopharyngeal cancer

    Oral Oncology

  3. Insulin degrading enzyme is up-regulated in pancreatic β cells by insulin treatment

    Histology and histopathology, Vol. 33, Núm. 11, pp. 1167-1180

2017

  1. S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison with Novel and Traditional Urothelial Immunohistochemical Markers

    Advances in Anatomic Pathology, Vol. 24, Núm. 3, pp. 151-160

2015

  1. A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 330-338

  2. Ewing-like sarcoma with CIC-DUX4 gene fusion in a patient with neurofibromatosis type 1. A hitherto unreported association

    Pathology Research and Practice, Vol. 211, Núm. 11, pp. 877-882

2013

  1. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome

    American Journal of Surgical Pathology, Vol. 37, Núm. 1, pp. 74-80

2012

  1. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior

    BMC Cancer, Vol. 12

  2. Serrated polyps of the colon: How reproducible is their classification?

    Virchows Archiv, Vol. 461, Núm. 5, pp. 495-504

  3. Study of KRAS new predictive marker in a clinical laboratory

    Clinical and Translational Oncology, Vol. 14, Núm. 12, pp. 937-942

2010

  1. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II

    Histology and Histopathology, Vol. 25, Núm. 3, pp. 341-349

2009

  1. Cáncer de riñón hereditario

    Actas Urologicas Espanolas, Vol. 33, Núm. 2, pp. 127-133

2007

  1. 17p13 (p53 locus), 5q21 (APC locus) and 9p21 (p16 locus) allelic deletions are frequently found in oral exfoliative cytology cells from smoker patients with non-small-cell lung cancer

    Histology and Histopathology, Vol. 22, Núm. 4-6, pp. 541-545